In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect
about
Biochemical stabilization of glucagon at alkaline pH.Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient.Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.Discomfort from an alkaline formulation delivered subcutaneously in humans: albumin at pH 7 versus pH 10.A review of artificial pancreas technologies with an emphasis on bi-hormonal therapyMechanisms of glucagon degradation at alkaline pH.Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreasEfficacy determinants of subcutaneous microdose glucagon during closed-loop control.Closed-loop systems: diversity and natural selection.Stability of Commercially Available Glucagon Formulation for Dual-Hormone Artificial Pancreas Clinical Use.Evaluation of the specific effects of intranasal glucagon on glucose production and lipid concentration in healthy men during a pancreatic clamp.Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue.
P2860
Q34360882-3D8B77E2-6DAB-4298-A818-056D43BF21C8Q35684921-E51E14A2-FBD9-4683-83F7-D68E7A8F6C71Q35830404-F4583429-E16E-4876-8495-5D1402438618Q36659766-B8CD43E9-DEF7-4554-AA3C-86B8AF369189Q36932650-89A81241-EF7F-4A98-BD9C-AEADB8C8E13CQ37154369-574C251C-9A6C-4C6D-9BB9-8341515DBB97Q37626914-0189ABA4-F7B3-46E6-A5C8-2BBEFC844DA5Q38042847-CE60025F-469A-4495-9742-2712BCDBE323Q41261537-EB25E818-2F3E-4C1E-8E48-8E672EC581CBQ42412112-5CEA91CB-50A4-460A-BE18-F98EC5CD4EC3Q47897234-12A1CEC1-15E0-4DF0-9EA2-7D84CE47C35AQ48089600-991CC2C2-991F-419C-B1D7-1FBF7CF213E1Q50131592-ADE193A8-E531-468D-AF57-3F76587C1B7C
P2860
In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In vitro and in vivo evaluatio ...... vation of hyperglycemic effect
@ast
In vitro and in vivo evaluatio ...... vation of hyperglycemic effect
@en
In vitro and in vivo evaluation of native glucagon and glucagon analog
@nl
type
label
In vitro and in vivo evaluatio ...... vation of hyperglycemic effect
@ast
In vitro and in vivo evaluatio ...... vation of hyperglycemic effect
@en
In vitro and in vivo evaluation of native glucagon and glucagon analog
@nl
prefLabel
In vitro and in vivo evaluatio ...... vation of hyperglycemic effect
@ast
In vitro and in vivo evaluatio ...... vation of hyperglycemic effect
@en
In vitro and in vivo evaluation of native glucagon and glucagon analog
@nl
P2093
P2860
P1476
In vitro and in vivo evaluatio ...... vation of hyperglycemic effect
@en
P2093
Charles T Roberts
Cory J Szybala
Joseph El Youssef
Julia M Engle
Julie M Carroll
Richard D DiMarchi
Ryan G Massoud
W Kenneth Ward
P2860
P304
P356
10.1177/193229681000400604
P577
2010-11-01T00:00:00Z